Publication Name	World Journal of Biological Chemistry
Manuscript ID	16488
Country	United States

Received	2015-01-20 09:29
Peer-Review Started	2015-01-20 17:43
To Make the First Decision	2015-02-07 15:03
Return for Revision	2015-02-10 16:31
Revised	2015-02-22 03:53
Second Decision	2015-04-10 18:21
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-04-20 14:46
Articles in Press	2015-04-20 14:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-05-04 08:39
Publish the Manuscript Online	2015-05-21 13:33

ISSN	1949-8454 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Research & Experimental Medicine
Manuscript Type	Editorial
Article Title	Promise and challenges on the horizon of MET-targeted cancer therapeutics
Manuscript Source	Invited Manuscript
All Author List	Yu-Wen Zhang
Funding Agency and Grant Number
Corresponding Author	Yu-Wen Zhang, MD, PhD, Center for Cancer and Cell Biology, Van Andel Research Institute, 333 Bostwick Ave NE, Grand Rapids, MI 49503, United States. yuwen.zhang@vai.org
Key Words	MET; Hepatocyte growth factor; Targeted therapy; Receptor tyrosine kinase; Cancer therapeutics
Core Tip	Aberrant activation of MET receptor tyrosine kinase signaling is frequently observed in many human cancers. Such activation not only affects cancer development and progression, but it also contributes to resistance against other cancer drugs. The inhibition of MET signaling is an attractive approach for cancer intervention, and pursuit of MET-targeted cancer therapeutics is underway. Even though promising results have been reported from various clinical trials, many challenges remain to be addressed before and even after the arrival of such drugs in the clinic.
Publish Date	2015-05-21 13:33
Citation	Zhang YW. Promise and challenges on the horizon of MET-targeted cancer therapeutics. World J Biol Chem 2015; 6(2): 16-27
URL	http://www.wjgnet.com/1949-8454/full/v6/i2/16.htm
DOI	http://dx.doi.org/10.4331/wjbc.v6.i2.16

Full Article (PDF)	WJBC-6-16.pdf
Full Article (Word)	WJBC-6-16.doc
Manuscript File	16488-Review.doc
Answering Reviewers	16488-Answering reviewers.pdf
Audio Core Tip	16488-Audio core tip.wav
Conflict-of-Interest Disclosure Form	16488-Conflict-of-interest statement.pdf
Copyright License Agreement	16488-Copyright assignment.pdf
Peer-review Report	16488-Peer-review(s).pdf
Scientific Misconduct Check	16488-Scientific misconduct check.pdf
Scientific Editor Work List	16488-Scientific editor work list.pdf